ESR1 and breast cancer: Overall, we demonstrated that induction of EMT can suppress estrogen signaling axis and vice versa, resulting in concurrent change in cellular phenotypes along both the EMP axis and in levels of drug resistance in ER+ breast cancer cells (Figure 3I).